The authors used in vitro and in vivo preclinical MDA prostate cancer PDX models of resistant human prostate cancer to determine molecular mechanisms of cross-resistance between anti-androgen therapy and taxane chemotherapy, underlying the therapeutically resistant phenotype.
[Molecular Cancer Research]
